| Item type |
文献 / Documents(1) |
| 公開日 |
2021-04-20 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/npr2.12098 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1002/npr2.12098 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Plasma levels of matrix metalloproteinase‐9 (MMP‐9) are associated with cognitive performance in patients with schizophrenia |
|
言語 |
en |
| 著者 |
クドウ, ノリコ
ヤマモリ, ヒデナガ
イシマ, タマキ
ネモト, キヨタカ
ヤスダ, ユカ
フジモト, ミチコ
アゼチ, ヒロツグ
ニイツ, トミヒサ
沼田, 周助
イケダ, マナブ
イヨ, マサオミ
大森, 哲郎
フクナガ, マサキ
ワタナベ, ヨシユキ
ハシモト, ケンジ
ハシモト, リョウタ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: Matrix metalloproteinase‐9 (MMP‐9) has been shown to modulate synaptic plasticity and may contribute to the pathophysiology of schizophrenia. This study investigated the peripheral levels of MMP‐9 and its association with cognitive functions in patients with schizophrenia to see the possible involvement of MMP‐9 in pathophysiology of schizophrenia, especially in cognitive decline.
Methods: We measured the plasma levels of MMP‐9 in 257 healthy controls and 249 patients with schizophrenia, including antipsychotic drug–free patients. We also explored the possible association between plasma MMP‐9 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS‐ III), the Wechsler Memory Scale‐Revised (WMS‐R), and the Rey Auditory Verbal Learning Test (AVLT).
Results: We found that the plasma levels of MMP‐9 were significantly higher in patients with schizophrenia, including antipsychotic drug–free patients, than in healthy controls. We found a significant negative association between plasma MMP‐9 levels and cognitive performance in controls and patients with schizophrenia.
Conclusion: Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased MMP‐9 levels are associated with cognitive impairment. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
cognitive performance |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
matrix metalloproteinase-9 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
schizophrenia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Wechsler Adult Intelligence Scale |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Wechsler Memory Scale |
| 書誌情報 |
en : Neuropsychopharmacology Reports
巻 40,
号 2,
p. 150-156,
発行日 2020-02-05
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2574173X |
| 出版者 |
|
|
出版者 |
The Japanese Society of Neuropsychopharmacology |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| EID |
|
|
識別子 |
365486 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
npr_40_2_150.pdf (428 KB)
.png)
